首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   6090篇
  免费   414篇
  国内免费   24篇
耳鼻咽喉   71篇
儿科学   237篇
妇产科学   137篇
基础医学   838篇
口腔科学   59篇
临床医学   793篇
内科学   1016篇
皮肤病学   117篇
神经病学   476篇
特种医学   308篇
外科学   772篇
综合类   324篇
一般理论   3篇
预防医学   465篇
眼科学   133篇
药学   373篇
中国医学   4篇
肿瘤学   402篇
  2021年   86篇
  2020年   52篇
  2019年   92篇
  2018年   88篇
  2017年   74篇
  2016年   72篇
  2015年   129篇
  2014年   111篇
  2013年   193篇
  2012年   244篇
  2011年   248篇
  2010年   185篇
  2009年   171篇
  2008年   232篇
  2007年   255篇
  2006年   282篇
  2005年   240篇
  2004年   284篇
  2003年   217篇
  2002年   217篇
  2001年   179篇
  2000年   176篇
  1999年   207篇
  1998年   102篇
  1997年   96篇
  1996年   103篇
  1995年   80篇
  1994年   72篇
  1993年   43篇
  1992年   118篇
  1991年   105篇
  1990年   122篇
  1989年   108篇
  1988年   105篇
  1987年   95篇
  1986年   110篇
  1985年   92篇
  1984年   75篇
  1983年   53篇
  1982年   47篇
  1981年   47篇
  1979年   83篇
  1978年   61篇
  1977年   58篇
  1976年   51篇
  1975年   37篇
  1974年   47篇
  1973年   55篇
  1972年   49篇
  1969年   38篇
排序方式: 共有6528条查询结果,搜索用时 4 毫秒
1.
2.
3.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
4.
5.
6.
OBJECTIVES: Physicians commonly use etomidate for adult rapid-sequence intubation (RSI), but the manufacturer does not recommend its use for children under 10 years of age due to a lack of data. The authors present their experience with etomidate for pediatric RSI in order to further develop its risk-benefit profile in this age group. METHODS: Trained abstractors reviewed the medical records for all children under 10 years old who received etomidate for RSI between July 1996 and April 2001. RESULTS: 105 children, with an average age of 3 (+/-2.9) years, received a median dose of 0.32 (+/-0.12) mg/kg of etomidate. The systolic blood pressure increased an average of 4 mm Hg (95% CI = -3.3 to 9.2); the diastolic blood pressure increased 7 mm Hg (95% CI = -3.1 to 11) within 10 minutes of receiving etomidate. The heart rate increased an average of 10 beats/min (95% CI = 4.0 to 17.4). Complications included three patients who vomited within 10 minutes of etomidate administration. There were no cases of documented myoclonus, status epilepticus, or new-onset seizures. Thirty-eight patients received corticosteroids during the hospital course, none for suspected adrenal insufficiency. Three patients died, all from severe brain injury. CONCLUSIONS: In children less than 10 years old, etomidate seems to produce minimal hemodynamic changes, and appears to have a low risk of clinically important adrenal insufficiency, myoclonus, and status epilepticus. The association between etomidate and emesis (observed in less than 3% of enrolled patients) remains unclear. For clinical situations in which minimal blood pressure changes during RSI are critical, etomidate appears to have a favorable risk-benefit profile for children under 10 years old.  相似文献   
7.
Sonoelasticity imaging of prostate cancer: in vitro results   总被引:2,自引:0,他引:2  
  相似文献   
8.
9.
10.

Background  

Acromioclavicular injuries are common in sports medicine. Surgical intervention is generally advocated for chronic instability of Rockwood grade III and more severe injuries. Various methods of coracoclavicular ligament reconstruction and augmentation have been described. The objective of this study is to compare the biomechanical properties of a novel palmaris-longus tendon reconstruction with those of the native AC+CC ligaments, the modified Weaver-Dunn reconstruction, the ACJ capsuloligamentous complex repair, screw and clavicle hook plate augmentation.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号